EJNMMI Research

Papers
(The H4-Index of EJNMMI Research is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Biodistribution and dosimetry of the PET radioligand [18F]CHDI-650 in mice for detection of mutant huntingtin aggregates41
Imaging tumor and ascites-associated macrophages in a mouse model of metastatic ovarian cancer39
18 F-Choline-PET/CT for non-FDG-avid salivary gland cancer: a preliminary report38
Change in brain amyloid load and cognition in patients with amnestic mild cognitive impairment: a 3-year follow-up study31
In vitro proof of concept studies of radiotoxicity from Auger electron-emitter thallium-20130
[123I]MIBG is a better early marker of anthracycline cardiotoxicity than [18F]FDG: a preclinical SPECT/CT and simultaneous PET/MR study30
Influence of corticosteroid treatment on CXCR4 expression in DLBCL27
Combatting the effect of image reconstruction settings on lymphoma [18F]FDG PET metabolic tumor volume assessment using various segmentation methods26
Early prediction of treatment outcome for lenvatinib using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, n26
[18F]F-FES PET for diagnosis, staging, and endocrine therapy prediction in ER-positive breast cancer: a systematic review and meta-analysis25
18F-FDG PET/CT-based deep learning radiomics predicts 5-years disease-free survival after failure to achieve pathologic complete response to neoadjuvant chemotherapy in breast cancer24
Adenosine-induced splenic switch-off on [15O]H2O PET perfusion for the assessment of vascular vasodilatation24
Hypometabolism and atrophy patterns associated with Niemann-Pick type C24
Toward in vivo proof of binding of 18F-labeled inhibitor [18F]TRACK to peripheral tropomyosin receptor kinases23
The value of radiomics based on 2-[18 F]FDG PET/CT in predicting WHO/ISUP grade of clear cell renal cell carcinoma22
First clinical experience with fractionated intracavitary radioimmunotherapy using [177Lu]Lu-6A10-Fab fragments in patients with glioblastoma: a pilot study21
All that glitters is not gold: high uptake on PSMA PET in non-prostate cancers does not mean that treatment with [177Lu]Lu-PSMA-radioligand will be successful21
Preliminary mechanistic insights of a brain-penetrant microtubule imaging PET ligand in a tau-knockout mouse model20
Quantification of [99mTc]Tc-HDP bone SPECT/CT: can we improve the body weight based standardized uptake value with a more robust normalization?20
Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A20
Predicting the effect of different folate doses on [68Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling20
0.13776278495789